Dexcom (NSDQ:DXCM) and Fitbit (NYSE:FIT) have partnered to develop and market continuous glucose monitoring technology for people with diabetes, the companies announced today.
The companies plan to integrate Dexcom’s CGM data with Fitbit’s new smartwatch, the Fitbit Ionic, so CGM users on Android or iOS devices can see their activity and glucose levels on their wrists.
“The strength of our brand and our ability to track critical health metrics continuously for up to 4+ days, coupled with Dexcom’s market leadership in CGM, present a powerful combination that we hope will help millions of people better manage their diabetes,” Fibit CEO James Park said in prepared remarks. “With Ionic, we are focused on driving positive health outcomes and more health focused tools, and this collaboration is a wonderful example of how we plan to bring that vision to our users.”
The companies hope to make their integrated product available as soon as possible in 2018 and left the option open for collaboration in the future.
“The collaboration between Dexcom and Fitbit is an important step in providing useful information to people with diabetes that is both convenient and discreet,” Dexcom president & CEO Kevin Sayer added. “We believe that providing Dexcom CGM data on Fitbit Ionic, and making that experience available to users of both Android and iOS devices, will have a positive impact on the way people manage their diabetes.”
People using Dexcom’s CGM will also be able to connect with Fitbit’s in-app community, the companies reported, where they can chat with other users.
FIT shares jumped 11% today, trading at $6.55 apiece in morning activity.
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
